CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
4-year survival and biomarkers evaluation from a phase II study of sequential immunotherapy and targeted therapy for metastatic BRAF V600-mutated melanoma (SECOMBIT)
Authors
Alessandro Marco Minisini
Ana Arance
+34 more
Antonio Cossu
Antonio M Grimaldi
Celeste Lebbe
Claudia Piccinini
Diana Giannarelli
Domenico Mallardo
Erika Richtig
Evaristo Maiello
Francesco Spagnolo
Giuseppe Palmieri
Helen Gogas
Hildur Helgadottir
Ignacio Melero
Jenny Bulgarelli
Luisa Piccin
Marco Tucci
Maria Gonzales Cao
Maria Grazia Vitale
Maria Teresa Fierro
Marina Pisano
Mario Mandalà
Michele Del Vecchio
Michele Guida
Miguel F Sanmamed
Milena Casula
Miriam Paone
Paola Queirolo
Paolo Antonio Ascierto
Pier Francesco Ferrucci
Piotr Rutkowski
Reinhard Dummer
Sabino De Placido
Vanna Chiarion Sileni
Virginia Ferraresi
Publication date
22 March 2023
Publisher
Doi
Cite
Abstract
4-year survival data of clinical trial SECOMBI
Similar works
Full text
Available Versions
ZENODO
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:zenodo.org:8386539
Last time updated on 06/10/2023